Transcatheter Aortic Valves (TAVI) - Medical Devices Pipeline Assessment, 2017

  • ID: 4429109
  • Report
  • 174 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Admedus Ltd
  • Colibri Heart Valve, LLC
  • Edwards Lifesciences Corp
  • JenaValve Technology GmbH
  • RegenaGraft
  • Symetis AG
  • MORE
Transcatheter Aortic Valves (TAVI) - Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, “Transcatheter Aortic Valves (TAVI) - Medical Devices Pipeline Assessment, 2017" provides an overview of Transcatheter Aortic Valves (TAVI) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transcatheter Aortic Valves (TAVI) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Transcatheter Aortic Valves (TAVI) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transcatheter Aortic Valves (TAVI) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transcatheter Aortic Valves (TAVI) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Admedus Ltd
  • Colibri Heart Valve, LLC
  • Edwards Lifesciences Corp
  • JenaValve Technology GmbH
  • RegenaGraft
  • Symetis AG
  • MORE
1 Table of Contents

2 Introduction
2.1 Transcatheter Aortic Valves (TAVI) Overview

3 Products under Development
3.1 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development
3.2 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Territory
3.3 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Regulatory Path
3.4 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Estimated Approval Date
3.5 Transcatheter Aortic Valves (TAVI) - Ongoing Clinical Trials

4 Transcatheter Aortic Valves (TAVI) - Pipeline Products under Development by Companies
4.1 Transcatheter Aortic Valves (TAVI) Companies - Pipeline Products by Stage of Development
4.2 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development

5 Transcatheter Aortic Valves (TAVI) Companies and Product Overview
5.1 Admedus Ltd Company Overview
5.1.1 Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.2 Aegis Surgical Limited Company Overview
5.2.1 Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview
5.3 Arbor Surgical Technologies, Inc. Company Overview
5.3.1 Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.4 Boston Scientific Corp Company Overview
5.4.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
5.5 Clemson University Company Overview
5.5.1 Clemson University Pipeline Products & Ongoing Clinical Trials Overview
5.6 Colibri Heart Valve, LLC Company Overview
5.6.1 Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.7 Daidalos Solutions BV Company Overview
5.7.1 Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview
5.8 Direct Flow Medical Inc Company Overview
5.8.1 Direct Flow Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.9 DSM Dyneema B.V. Company Overview
5.9.1 DSM Dyneema B.V. Pipeline Products & Ongoing Clinical Trials Overview
5.10 Edwards Lifesciences Corp Company Overview
5.10.1 Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview
5.11 Hansen Medical Inc Company Overview
5.11.1 Hansen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.12 HLT, Inc. Company Overview
5.12.1 HLT, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.13 JC Medical, Inc. Company Overview
5.13.1 JC Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.14 JenaValve Technology GmbH Company Overview
5.14.1 JenaValve Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.15 Mayo Clinic US Company Overview
5.15.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview
5.16 Medtronic plc Company Overview
5.16.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
5.17 Meril Life Sciences Pvt Ltd Company Overview
5.17.1 Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.18 MicroPort Scientific Corp Company Overview
5.18.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
5.19 PolyNova Cardiovascular LLC (Inactive) Company Overview
5.19.1 PolyNova Cardiovascular LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.20 RegenaGraft Company Overview
5.20.1 RegenaGraft Pipeline Products & Ongoing Clinical Trials Overview
5.21 ReValve Med Inc Company Overview
5.21.1 ReValve Med Inc Pipeline Products & Ongoing Clinical Trials Overview
5.22 SAS Cormove Company Overview
5.22.1 SAS Cormove Pipeline Products & Ongoing Clinical Trials Overview
5.23 St. Jude Medical LLC Company Overview
5.23.1 St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
5.24 Symetis AG Company Overview
5.24.1 Symetis AG Pipeline Products & Ongoing Clinical Trials Overview
5.25 Thubrikar Aortic Valve, Inc. Company Overview
5.25.1 Thubrikar Aortic Valve, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.26 University College London Company Overview
5.26.1 University College London Pipeline Products & Ongoing Clinical Trials Overview
5.27 University of California San Francisco Company Overview
5.27.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview
5.28 University of Cambridge Company Overview
5.28.1 University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview
5.29 University of Iowa Company Overview
5.29.1 University of Iowa Pipeline Products & Ongoing Clinical Trials Overview
5.30 Vascular Concepts Ltd Company Overview
5.30.1 Vascular Concepts Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.31 Venus MedTech Company Overview
5.31.1 Venus MedTech Pipeline Products & Ongoing Clinical Trials Overview
5.32 Xeltis AG Company Overview
5.32.1 Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview

6 Transcatheter Aortic Valves (TAVI)- Recent Developments
6.1 Oct 26, 2017: HLT to Provide Clinical Update at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) Conference
6.2 Oct 26, 2017: MicroPort CardioFlow Attends 2017 PCR London Valves
6.3 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017
6.4 Oct 24, 2017: Admedus TAVR Project on Track with New IP Applications
6.5 Oct 24, 2017: Edwards Lifesciences Announces Third Quarter Results
6.6 Oct 23, 2017: Boston Scientific Presents Study Results of ACURATE neo Aortic Valve System at Transcatheter Cardiovascular Therapeutics 2017
6.7 Oct 23, 2017: Boston Scientific Presents Study Results of Lotus Aortic Valve System at Transcatheter Cardiovascular Therapeutics 2017
6.8 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria
6.9 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary
6.10 Sep 21, 2017: Medtronic Announces Clinical Study to Evaluate the CoreValve Evolut PRO System in 'Everyday' Clinical Practice
6.11 Aug 22, 2017: Medtronic Reports First Quarter Financial Results
6.12 Jul 31, 2017: Medtronic Announces CE Mark and European Launch of CoreValve Evolut PRO Transcatheter Valve with Advanced Sealing
6.13 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017
6.14 Jul 10, 2017: Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
6.15 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day
6.16 Jun 06, 2017: First U.S. Patients Enrolled in an Early Feasibility Study of HLT's New Transcatheter Aortic Valve Replacement System
6.17 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results
6.18 May 17, 2017: Edwards' Novel Self-Expanding Transcatheter Heart Valve Demonstrates Excellent Early Patient Outcomes
6.19 May 16, 2017: Real-World Evidence With Edwards SAPIEN 3 Transcatheter Valve Confirms Beneficial Patient Outcomes From Clinical Trials
6.20 May 16, 2017: The Boston Scientific LOTUS Valve System Demonstrated Superior Efficacy to CoreValve in Global REPRISE III Trial at One Year
6.21 May 16, 2017: New Data on CoreValve and Evolut R Self-Expanding TAVI Systems Show Excellent Clinical Outcomes in Routine Clinical Practice
6.22 Apr 28, 2017: Venus Medtech's TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China English
6.23 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017
6.24 Apr 25, 2017: Edwards Lifesciences Reports First Quarter Results
6.25 Apr 05, 2017: Aurora Health Care Heart Experts Among First in Nation to Implant New Heart Valve to Treat Aortic Stenosis
6.26 Apr 04, 2017: HLT Announces First Patient Enrollments in a Feasibility Study of a New Transcatheter Aortic Valve Replacement System
6.27 Mar 22, 2017: Medtronic Receives FDA Approval for CoreValve Evolut Pro Transcatheter Valve with Advanced Sealing
6.28 Mar 17, 2017: Landmark SURTAVI Clinical Trial Shows Transcatheter Aortic Valve Replacement with the Self-Expanding Platform Performs as Well as Surgery in Intermediate Risk Severe Aortic Stenosis Patients
6.29 Mar 09, 2017: Boston Scientific Receives Favorable Rulings In Edwards Lifesciences Litigation
6.30 Mar 03, 2017: Colibri Heart Valve Receives ISO 13485 and EN ISO 13485 Certification
6.31 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results
6.32 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors
6.33 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016
6.34 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results
6.35 Jan 17, 2017: Medtronic Announces CE Mark and European Launch of Recaptureable TAVI System Now Available for Severe Aortic Stenosis Patients with Large Anatomies
6.36 Dec 26, 2016: MicroPort Completes Patient Enrollment of VitaFlow Pre-market Clinical Trial
6.37 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
6.38 Dec 01, 2016: Medtronic Announces Reimbursement Approval and Launch of CoreValve Evolut R System in Japan
6.39 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results
6.40 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report
6.41 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction

7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development
Table 2: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Territory
Table 3: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Regulatory Path
Table 4: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Estimated Approval Date
Table 5: Transcatheter Aortic Valves (TAVI) - Ongoing Clinical Trials
Table 6: Transcatheter Aortic Valves (TAVI) Companies - Pipeline Products by Stage of Development
Table 7: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development
Table 8: Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Transcatheter Aortic Valve Replacement - Product Status
Table 10: Transcatheter Aortic Valve Replacement - Product Description
Table 11: Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview
Table 12: pTAo-TAVR - Product Status
Table 13: pTAo-TAVR - Product Description
Table 14: Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Trilogy Aortic Valve System - Product Status
Table 16: Trilogy Aortic Valve System - Product Description
Table 17: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 18: ACURATE TAVR - Product Status
Table 19: ACURATE TAVR - Product Description
Table 20: Gen 4 Lotus Valve System - Product Status
Table 21: Gen 4 Lotus Valve System - Product Description
Table 22: Lotus Edge Sheath 15F - Product Status
Table 23: Lotus Edge Sheath 15F - Product Description
Table 24: Lotus Edge Valve System - 21 mm - Product Status
Table 25: Lotus Edge Valve System - 21 mm - Product Description
Table 26: Lotus Edge Valve System - 23 mm - Product Status
Table 27: Lotus Edge Valve System - 23 mm - Product Description
Table 28: Lotus Edge Valve System - 25 mm - Product Status
Table 29: Lotus Edge Valve System - 25 mm - Product Description
Table 30: Lotus Edge Valve System - 27 mm - Product Status
Table 31: Lotus Edge Valve System - 27 mm - Product Description
Table 32: Lotus Edge Valve System - 29 mm - Product Status
Table 33: Lotus Edge Valve System - 29 mm - Product Description
Table 34: LOTUS Next Gen - Product Status
Table 35: LOTUS Next Gen - Product Description
Table 36: Lotus Valve System - 21 mm - Product Status
Table 37: Lotus Valve System - 21 mm - Product Description
Table 38: Lotus Valve System - 23 mm - Product Status
Table 39: Lotus Valve System - 23 mm - Product Description
Table 40: Lotus Valve System - 25 mm - Product Status
Table 41: Lotus Valve System - 25 mm - Product Description
Table 42: Lotus Valve System - 27 mm - Product Status
Table 43: Lotus Valve System - 27 mm - Product Description
Table 44: Lotus Valve System - 29 mm - Product Status
Table 45: Lotus Valve System - 29 mm - Product Description
Table 46: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 47: Lotus Valve System - 23 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 48: Lotus Valve System - 23 mm - Experience with Percutaneous Transcatheter Aortic Valve Implantation in Patients with Symptomatic Aortic Valve Disease in Two German Centers
Table 49: Lotus Valve System - 23 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 50: Lotus Valve System - 23 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 51: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China
Table 52: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan
Table 53: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety:REPRISE II FLEX
Table 54: Lotus Valve System - 23 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 55: Lotus Valve System - 27 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 56: Lotus Valve System - 27 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 57: Lotus Valve System - 27 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 58: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China
Table 59: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan
Table 60: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety:REPRISE II FLEX
Table 61: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS)
Table 62: Lotus Valve System - 27 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 63: Lotus Valve System - 25 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 64: Lotus Valve System - 25 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 65: Lotus Valve System - 25 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 66: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China
Table 67: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan
Table 68: Lotus Valve System - 25 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 69: Lotus Valve System - 21 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 70: Lotus Valve System - 21 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 71: Lotus Valve System - 21 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 72: Lotus Valve System - 21 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 73: Lotus Valve System - 29 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 74: Lotus Valve System - 29 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 75: Lotus Valve System - 29 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 76: Lotus Valve System - 29 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 77: Lotus Edge Valve System - 23 mm - Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation
Table 78: Lotus Edge Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS)
Table 79: Lotus Edge Valve System - 23 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety
Table 80: Lotus Edge Valve System - 29 mm - Reprise Edge 29 Mm Eu Study: Repositionable Percutaneous Replacement of Native Stenotic Aortic Valve Through Implantation of Lotus Edge 29 Mm Valve - Evaluation of Safety and Performance
Table 81: Lotus Edge Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS)
Table 82: Lotus Edge Valve System - 25 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety
Table 83: Lotus Edge Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS)
Table 84: Lotus Edge Valve System - 27 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety
Table 85: Clemson University Pipeline Products & Ongoing Clinical Trials Overview
Table 86: Transcatheter Bioprosthetic Heart Valve - Product Status
Table 87: Transcatheter Bioprosthetic Heart Valve - Product Description
Table 88: Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 89: Colibri Aortic Heart Valve - 24mm - Product Status
Table 90: Colibri Aortic Heart Valve - 24mm - Product Description
Table 91: Colibri Aortic Heart Valve - 21mm - Product Status
Table 92: Colibri Aortic Heart Valve - 21mm - Product Description
Table 93: Colibri Aortic Heart Valve - 27mm - Product Status
Table 94: Colibri Aortic Heart Valve - 27mm - Product Description
Table 95: Colibri TAVI System - Product Status
Table 96: Colibri TAVI System - Product Description
Table 97: Delta Aortic Heart Valve - Product Status
Table 98: Delta Aortic Heart Valve - Product Description
Table 99: Venibri Transcatheter Heart Valve System - Product Status
Table 100: Venibri Transcatheter Heart Valve System - Product Description
Table 101: Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview
Table 102: Sutureless Trans-Catheter Aortic Valve Replacement (TAVR) - Product Status
Table 103: Sutureless Trans-Catheter Aortic Valve Replacement (TAVR) - Product Description
Table 104: Direct Flow Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 105: 18F Direct Flow Medical Transcatheter Aortic Valve System - Product Status
Table 106: 18F Direct Flow Medical Transcatheter Aortic Valve System - Product Description
Table 107: 23mm Direct Flow Medical Transcatheter Aortic Valve System - Product Status
Table 108: 23mm Direct Flow Medical Transcatheter Aortic Valve System - Product Description
Table 109: Direct Flow Medical Inc - Ongoing Clinical Trials Overview
Table 110: 18F Direct Flow Medical Transcatheter Aortic Valve System - A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System for the Treatment of Patients with Severe Aortic Stenosis
Table 111: 18F Direct Flow Medical Transcatheter Aortic Valve System - SALUS Trial Transcatheter Aortic Valve Replacement System Pivotal Trial the Safety and Effectiveness of the Direct Flow Medical Tanscatheter Aortic Valve System
Table 112: DSM Dyneema B.V. Pipeline Products & Ongoing Clinical Trials Overview
Table 113: Dyneema Purity - Transcatheter Heart Valve - Product Status
Table 114: Dyneema Purity - Transcatheter Heart Valve - Product Description
Table 115: Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 116: Edwards CENTERA Valve - Product Status
Table 117: Edwards CENTERA Valve - Product Description
Table 118: Edwards SAPIEN 3 Transcatheter Heart Valve - Low Risk - Product Status
Table 119: Edwards SAPIEN 3 Transcatheter Heart Valve - Low Risk - Product Description

List of Figures
Figure 1: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development
Figure 2: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Territory
Figure 3: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Regulatory Path
Figure 4: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Estimated Approval Date
Figure 5: Transcatheter Aortic Valves (TAVI) - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Admedus Ltd
  • Aegis Surgical Limited
  • Arbor Surgical Technologies, Inc.
  • Boston Scientific Corp
  • Clemson University
  • Colibri Heart Valve, LLC
  • Daidalos Solutions BV
  • Direct Flow Medical Inc
  • DSM Dyneema B.V.
  • Edwards Lifesciences Corp
  • Hansen Medical Inc
  • HLT, Inc.
  • JC Medical, Inc.
  • JenaValve Technology GmbH
  • Mayo Clinic US
  • Medtronic plc
  • Meril Life Sciences Pvt Ltd
  • MicroPort Scientific Corp
  • PolyNova Cardiovascular LLC
  • RegenaGraft
  • ReValve Med Inc
  • SAS Cormove
  • St. Jude Medical LLC
  • Symetis AG
  • Thubrikar Aortic Valve, Inc.
  • University College London
  • University of California San Francisco
  • University of Cambridge
  • University of Iowa
  • Vascular Concepts Ltd
  • Venus MedTech
  • Xeltis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll